* If you want to update the article please login/register
Anaplastic large cell lymphoma is a rare mature T-cell non-Hodgkin's lymphoma with extensive and pleomorphic neoplastic T cells. Breast implant-associated ALCL contains three main cutaneous ALCL subtypes with different clinical and biological characteristics: systemic ALCL, primary cutaneous ALCL, and breast implant-associated ALCL. In several systemic cases, an anaplastic lymphoma kinase is overexpressed and rearranged. The periprosthetic fluid was included in lymph nodes and skin lesions in a Cytological study. In 8 cases and one case, FNAC was performed on lymph nodes and on skin lesion. In three cases, breast periprosthetic fluids were tested. In every case, and FISH in three instances, ALK rearrangement was confirmed in a case of ALK+ ALCL. A large immunochemical panel was employed in each case, as well as FISH in three cases, demonstrating ALK rearrangement. It was likely that systemic ALCL and primary cutaneous ALCL were both possible in the case of skin lesion. FISH may be useful in determining ALK rearrangements.
Source link: https://europepmc.org/article/MED/36634640
This is the first instance of anaplastic large cell lymphoma following after complete knee replacement arthroplasty. An 80-year-u2011 female patient was admitted to hospital due to right knee pain for two years. Histologic results show sheets of anaplastic tumor cells were positive for CD2, CD4, CD5, CD43, and CD30, but not for CD3, CD20, CD15, and anaplastic lymphoma kinase. Monoclonal T cell proliferation was confirmed by tissue culture using BIOMED-2-based multiplex polymerase chain reaction.
Source link: https://europepmc.org/article/MED/36623817
The Children's Oncology Group trial ANHL12P1 investigated the effectiveness and danger of adding CZ to standard chemotherapy for children with newly diagnosed, non-localized ALK+ anaplastic large-cell lymphoma. Fifteen patients relapsed and one patient died, and the overall time to relapse was 7. 4 months from diagnosis, with relapses occurring after chemotherapy was complete. Patients with negative MDD had a superior result, with an EFS of 85. 6%; positive MDD had a lower EFS of 58. 1%. The addition of CZ to standard therapy prevented relapses during therapy for children with ALCL, MDD expected EFS, and unexpected thromboembolic events, according to Arm CZ of ANHL12P1. Overall survival and EFS rates for children with ALCL remain stable, with the highest reported outcomes for children with ALCL.
Source link: https://europepmc.org/article/MED/36534942
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions